Heart safety check for cancer drug selpercatinib
NCT ID NCT05630274
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at whether a single dose of selpercatinib, a cancer drug, changes the heart's electrical activity (QT interval) in 32 healthy adults. Participants received selpercatinib, a placebo, or a control drug (moxifloxacin) in a crossover design. The main goal was to measure any heart rhythm effects to ensure the drug's safety for future use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selpercatinib (also known as LOXO-292)
- What this could lead to
- If successful, this study will confirm that selpercatinib does not cause dangerous heart rhythm changes, supporting its safe use in patients.
- What could go wrong
- This is a small, early-phase study in healthy volunteers, not patients. Heart effects seen here may differ in sicker populations or with long-term use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test